How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

47 results for

Campral

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Campral

Campral Campral Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Campral Campral Aka: Campral , Acamprosate From Related Chapters II (...) . Indications Maintenance of abstinence III. Contraindications Severe ( <30 ml/min) Advanced (although appears safe in most with impaired hepatic function) IV. Mechanism Balances GABA and glutamate neurotransmitters Blocks glutaminergic N-methyl-D- ate receptors Activates GABA Type A receptors Reduces anxiety from abstinence V. Efficacy Reduces short and longterm relapse rates Sustains abstinence (NNT 12) and reduces (NNT 9) VI. Dosing Campral 666 mg (two 333 mg tabs) orally three times daily Start with one

2018 FP Notebook

2. Campral

Campral Campral Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Campral Campral Aka: Campral , Acamprosate From Related Chapters II (...) . Indications Maintenance of abstinence III. Contraindications Severe ( <30 ml/min) Advanced (although appears safe in most with impaired hepatic function) IV. Mechanism Balances GABA and glutamate neurotransmitters Blocks glutaminergic N-methyl-D- ate receptors Activates GABA Type A receptors Reduces anxiety from abstinence V. Efficacy Reduces short and longterm relapse rates Sustains abstinence (NNT 12) and reduces (NNT 9) VI. Dosing Campral 666 mg (two 333 mg tabs) orally three times daily Start with one

2015 FP Notebook

3. Is Campral ok to be used in a chronic alcoholic with abnormal LFTs (eg ALT of 350)?

Is Campral ok to be used in a chronic alcoholic with abnormal LFTs (eg ALT of 350)? Is Campral ok to be used in a chronic alcoholic with abnormal LFTs (eg ALT of 350)? - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches (...) types including images, videos, patient information leaflets, educational courses and news. For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com Is Campral ok to be used in a chronic alcoholic with abnormal LFTs (eg ALT of 350)? We found no information concerning the suitability of prescribing acamprosate to a patient with abnormal liver function tests, namely

2008 TRIP Answers

4. Naltrexone for Alcohol Dependence: Clinical Effectiveness

identified regarding naltrexone for the treatment of alcohol dependence. Tags alcohol deterrents, alcohol drinking, alcoholics anonymous, alcohol-related disorders, naltrexone, addiction, alcohol abuse, alcohol addiction, alcohol use disorder, Alcoholic, Alcoholics, Alcoholism, Campral, Celupan, Trexan, Vivitrol, Vivitrex, ReVia, Depade Files Rapid Response Reference List Published : January 3, 2017 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Long-term Use of Acamprosate Calcium for Alcoholism

articles were retrieved and assessed for inclusion. The final selection of full-text articles was based on the inclusion criteria presented in Table 1. Table 1: Selection Criteria Population Adults with alcoholism Intervention Acamprosate calcium (Campral) for longer than one year Comparator Any comparator (placebo, no treatment, other active treatment) No comparator Outcomes Clinical effectiveness (e.g. alcohol abstinence) Safety Evidence-based guidelines for use Study Designs Health technology

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Validation of a Test System to Develop New Medications for Alcoholism (TEMACA)

Date : August 30, 2020 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Acamprosate 1 capsule with Acamprosate calcium oral use 3 times / day (morning, noon, evening) 666 mg per capsule 14 - 19 days Drug: Acamprosate Calcium 1 capsule with 666 mg Acamprosate 1 capsule with 950 mg Calcium Citrate Other Name: Campral Drug: Placebo lead in 1 Capsule with Placebo (lactose monohydrate

2018 Clinical Trials

7. Medication Development in Alcoholism: Apremilast Versus Placebo

participation as determined by the study physician Known hypersensitivity to apremilast Treatment within the month prior to screening with (1) an investigational drug, (2) medications which may negatively interact with study medications, or (3) drugs that may influence study outcomes (e.g., disulfiram [Antabuse], naltrexone [ReVia], acamprosate [Campral], anticonvulsants, or antidepressants). Ongoing treatment with medications that may increase risk, including prescribed, over-the-counter, and herbal

2017 Clinical Trials

8. Study of Acamprosate in Autism

for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg. Other Name: Campral Drug: Acamprosate The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg. Other Name: Campral Outcome Measures Go to Primary Outcome Measures : Change from baseline to week 10 on the Social WIthdrawal subscale of ABC [ Time Frame: Week 10 ] The subscales

2013 Clinical Trials

9. Study of Acamprosate in Fragile x Syndrome

daily (total 1998 mg/day) for subjects weight ≥ 50 kg and 1332mg for subjects that weigh < 50 kg. Drug: acamprosate Other Name: Campral Placebo Comparator: Placebo Placebo will be prescribed with the same frequency and duration as the acamprosate group. Drug: Placebo Outcome Measures Go to Primary Outcome Measures : Aberrant Behavior Checklist-Social Withdrawal subscale [ Time Frame: Change from baseline to week 10 ] The ABC is the gold standard parent/caregiver reported behavioral outcome measure

2013 Clinical Trials

10. Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists

with 1.) an investigational drug or vaccine; 2.) drugs that may influence study outcomes, e.g., disulfiram (Antabuse), naltrexone (ReVia), acamprosate (Campral), anticonvulsants, antidepressants. In need of or currently taking any psychoactive medications. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study

2012 Clinical Trials

11. Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults

in the past 1 month prior to screening with disulfiram (Antabuse), acamprosate (Campral), naltrexone (ReVia or Vivitrol), or topiramate (Topamax) In need of or currently taking any psychoactive medications Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number

2011 Clinical Trials

12. Addiction 2.0 Part 2

is indeed intended to be brief – only 5-10 minutes of discussion with a patient per session has been shown to be an effective intervention (http:/niaaa.gov/cliniciansguide2008/). Pharmacotherapies for Alcohol . With the 2006 FDA approval of extended-release naltrexone (XR-NTX, Vivitrol), the physician has four FDA-labeled agents available for the treatment of alcohol dependence: disulfiram (Antabuse), oral naltrexone (ReVia, 1994), acamprosate (Campral, 2004), and extended-release naltrexone. The recent

2008 Clinical Correlations

13. Acamprosate

Acamprosate Acamprosate - Wikipedia Acamprosate From Wikipedia, the free encyclopedia Acamprosate Clinical data Campral EC Synonyms N-Acetyl homotaurine, Acamprosate calcium ( C > ( ) B2 ( ) Oral ( ) Legal status (Prescription only) (Prescription only) data 11% Negligible Nil 20 h to 33 h Identifiers 3-Acetamidopropane-1-sulfonic acid Y Y Y Y Y N Chemical and physical data C 5 H 11 N O 4 S 181.211 g/mol g·mol −1 3D model ( ) [Ca+2].O=C(NCCCS(=O)(=O)[O-])C.[O-]S(=O)(=O)CCCNC(=O)C InChI=1S (...) /2C5H11NO4S.Ca/c2*1-5(7)6-3-2-4-11(8,9)10;/h2*2-4H2,1H3,(H,6,7)(H,8,9,10);/q;;+2/p-2 Y Key:BUVGWDNTAWHSKI-UHFFFAOYSA-L Y N Y Acamprosate , sold under the brand name Campral , is a medication used along with counselling to treat . Acamprosate is thought to stabilize that would otherwise be disrupted by alcohol withdrawal. When used alone, acamprosate is not an effective therapy for in most individuals; studies have found that acamprosate works best when used in combination with psychosocial support since

2012 Wikipedia

14. Acamprosate in Youth With Fragile X Syndrome

: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Acamprosate The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 60kg and 1332 mg per day for those less weighing less than 60kg. Drug: Acamprosate Other Name: Campral No Intervention: Autism Spectrum Disorder This baseline comparison group will participated in only the psychophysiological and biomarker portion of subject characterization

2010 Clinical Trials

15. Duloxetine Versus Pregabalin for Alcohol Dependence

with an antidepressant medication during the two weeks, or fluoxetine during the month, prior to randomization Ongoing treatment with disulfiram (Antabuse), naltrexone (ReVia), acamprosate (Campral) or other medications that may affect study outcomes, e.g., anticonvulsants or other drugs that act on serotonin in the brain Ongoing treatment with drugs that may increase potential risk (Actos), Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your

2009 Clinical Trials

16. Alcohol Detoxification in Primary Care Treatment (ADEPT)

. Study Start Date : November 2009 Actual Primary Completion Date : July 2010 Actual Study Completion Date : November 2010 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Intervention Details: Drug: Acamprosate Acamprosate 333mg tablets, two tablets three times a day for duration of alcohol detox. Other Name: Campral Outcome Measures Go to Primary Outcome Measures : Reduction in alcohol withdrawal symptoms [ Time Frame: up to 10

2009 Clinical Trials

17. Alcohol treatment effects on secondary nondrinking outcomes and quality of life: the COMBINE study. (PubMed)

, a multisite clinical trial of pharmacological (naltrexone [ReVia] and acamprosate [Campral]) and behavioral interventions, to examine the effects of specific treatment combinations on nondrinking functional outcomes. We assessed the outcomes at baseline and at the end of 16 weeks of alcohol treatment and again at the 26-week and/or 52-week postrandomization follow-ups.(1) Drinking and secondary outcomes were significantly related, especially at the follow-up periods. A higher percentage of heavy drinking

Full Text available with Trip Pro

2009 Journal of studies on alcohol and drugs

18. Treatment Implications: Using Neuroscience to Guide the Development of New Pharmacotherapies for Alcoholism (PubMed)

Treatment Implications: Using Neuroscience to Guide the Development of New Pharmacotherapies for Alcoholism Developing pharmacotherapies to treat alcohol dependence and associated health problems traditionally has been based on gaining a better understanding of the neuroscience underlying alcohol-drinking behavior. To date, three medications have been approved for the treatment of alcohol dependence: disulfiram (Antabuse®), naltrexone (Revia®, Vivitrol®, and Naltrel®), and acamprosate (Campral®

Full Text available with Trip Pro

2008 Alcohol Research & Health

19. Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)

based treatment programs (Chick et al. 2003). There is limited data on the safety of acamprosate in the elderly (PDR 2005). For the purposes of this study, elderly will be defined as 60 years or older. STUDY OBJECTIVE: To determine the short-term safety of Acamprosate in the treatment of alcohol dependence in the elderly. Condition or disease Intervention/treatment Phase Alcohol Dependence Drug: Acamprosate (Campral) Drug: Acamprosate Phase 4 Detailed Description: STUDY DESIGN: This trial (...) Masking: None (Open Label) Primary Purpose: Treatment Official Title: Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study Study Start Date : December 2006 Estimated Primary Completion Date : December 2008 Estimated Study Completion Date : December 2008 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: 1 Acamprosate(Campral) Drug: Acamprosate (Campral) During

2008 Clinical Trials

20. Acamprosate: Genes Associated With Response

of effective individualized treatment recommendations for alcohol dependent patients based on pharmacogenomically relevant genetic variations. There will be no placebo drug given. Just measurement of genetic response. Drug: acamprosate acamprosate 333mg tabs, 2tabs 3times per day = 1998mg/day Other Name: Campral is the brand name of acamprosate. Outcome Measures Go to Primary Outcome Measures : Aim 1: To determine the relationship between genetically determined variation in the NMDA receptor and treatment

2008 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>